Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Anaplastic Ependymoma: early-phase trial registry

2 of 6 indexed Anaplastic Ependymoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Anaplastic Ependymoma: 6 US clinical trials tracked, 2 recruiting.

Anaplastic Ependymoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 2 of these trials.

Enrollment posture brief

Registry condition anaplastic-ependymoma

OPEN 2 | RECR 33% | LATE 1 | EARLY 5 | RANK #2866 | SPON 2

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Anaplastic Ependymoma (this)33%
Open-enrollment share among volume-matched conditions near Anaplastic Ependymoma

Anaplastic Ependymoma lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anaplastic Ependymoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anaplastic Ependymoma is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Anaplastic Ependymoma research.

    Children's Oncology Group accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Anaplastic Ependymoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.

  4. Anaplastic Ependymoma research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 31

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 3 1

Named interventions

Most-linked intervention names on Anaplastic Ependymoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Lapatinib Ditosylate Drug
1 trials
therapeutic allogeneic lymphocytes Biological
1 trials
aldesleukin Biological
1 trials
SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years Biological
1 trials
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years Biological
1 trials
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years Biological
1 trials
Pharmacological Study Other
1 trials
Lapatinib Drug
1 trials

US sites by state

Facility locations filed on Anaplastic Ependymoma trials. A trial with sites in several states counts in each.

California 4 trials
Pennsylvania 3 trials
Ohio 3 trials
Texas 2 trials
New York 2 trials
Massachusetts 2 trials
Colorado 2 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anaplastic Ependymoma page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Ependymoma condition card totals 6 registered trials; most-linked intervention Lapatinib Ditosylate; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.